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Abstract
Background:  The neuroleptic malignant syndrome is a rare but serious condition mainly
associated with antipsychotic medication. There are controversies as to whether "classical" forms
of neuroleptic malignant syndrome can occur in patients given atypical antipsychotics. The
serotonin syndrome is caused by drug-induced excess of intrasynaptic 5-hydroxytryptamine. The
possible relationship between neuroleptic malignant syndrome and serotonin syndrome is at
present in the focus of scientific interest.
Methods: This retrospective phenomenological study aims to examine the seventeen reported
olanzapine – induced neuroleptic malignant syndrome cases under the light of possible overlap
between neuroleptic malignant syndrome and serotonin syndrome clinical features.
Results: The serotonin syndrome clinical features most often reported in cases initially diagnosed
as neuroleptic malignant syndrome are: fever (82%), mental status changes (82%) and diaphoresis
(47%). Three out of the ten classical serotonin syndrome clinical features were concurrently
observed in eleven (65%) patients and four clinical features were observed in seven (41%) patients.
Conclusion: The results of this study show that the clinical symptoms of olanzapine-induced
neuroleptic malignant syndrome and serotonin syndrome are overlapping suggesting similarities in
underlying pathophysiological mechanisms.
Background
The neuroleptic malignant syndrome (NMS) is a rare but
potentially fatal condition associated with antipsychotic
medication. It is mainly characterized by fever, extrapy-
ramidal symptoms, autonomic instability and an altered
state of consciousness. It is primarily caused by dopamine
(D2) receptors blockage in the nigrostriatal tract, mesocor-
tical pathway and hypothalamic nuclei [1]. Recently,
many authors have expressed the view that NMS is not
caused by dopamine block alone. Other aminergic sys-
tems have also been implicated such as serotonin, nore-
pinephrine, GABA e.t.c. [1,2]. There are controversies as to
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whether atypical antipsychotics can cause "classical"
forms of NMS [3–5].
During the last years, a condition of serotoninergic hyper-
stimulation called "serotonin syndrome" (SS) has been
described. It is mainly associated with administration of
antidepressive medication. The most frequent clinical fea-
tures of this syndrome are changes in mental status, rest-
lessness, myoclonus and hyperreflexia [6].
The difficulty of differentiating between NMS and SS has
been well recognized [7,8].
Olanzapine is an atypical antipsychotic, which exhibits
greater affinity to serotonin (5-HT2) receptors than to
dopamin (D2) receptors [9].
The aim of this study was to examine the recently reported
NMS cases induced by olanzapine regarding SS clinical
features and to elucidate phenomenological similarities
between the two syndromes.
Methods
A MEDLINE search related to olanzapine-induced NMS
cases reported in the international literature from January
1996 to March 2001 was conducted. On the basis of the
titles and information included in the abstracts, seventeen
case reports were found [10–26]. Olanzapine-induced
NMS cases have been presented and critically reviewed
elswhere [27]. All cases were re-analyzed against SS clini-
cal features according to Sternbach diagnostic criteria [6].
Results
NMS associated with olanzapine has been reported in
twelve males (mean age 44.5 ± 20.9 years) and in five
females (mean age 54.2 ± 22.4 years). Schizophrenia was
the primary diagnosis in nine of the patients (53%). The
mean olanzapine dosage was 10.7 ± 4.3 mg/day.
As shown in table 1, the SS clinical features presented in
cases initially diagnosed as NMS were the following: fever
(82%), mental status changes (82%), diaphoresis (47%),
tremor (35%), agitation (23%), hyperreflexia (18%),
incoordination (12%), myoclonus (6%), diarrhea (6%).
There was no report on shivering.
Three out of the ten SS clinical features set by Sternbach
[6] were concurrently observed in eleven (65%) patients.
Four clinical features were observed in seven (41%)
patients and five clinical features in two (12%) patients.
Discussion
According to Sternbach [6], for the establishment of the
diagnosis of SS, the following three criteria should be ful-
filled: a. presence of at least three of the ten proposed clin-
ical features, b. addition to the therapeutic regiment or
increase of a known serotonergic agent, and c. a neurolep-
tic had not been started or increased in dosage. If the last
two criteria of drug use were excluded, the SS diagnosis in
olanzapine-associated NMS cases could be made in eleven
patients (65%). This means that there is a phenomenolog-
ical overlap between NMS and SS symptoms in patients
on olanzapine treatment. According to several authors
NMS and SS can be differentiated with difficulty in many
Table 1: Serotonin syndrome clinical features presented in NMS cases induced by olanzapine
Case Reference MS A MY H D S T DI I F
1 Johnson & Bruxner 10 + ++
2 Filice et al11 ++ + +
3 Moltz & Coeytaux12 ++ + +
4 Henel et al13 ++ + +
5 Burkhard et al 14 ++ ++
6 Emborg15 + +
7 Apple & Van Hauer16 ++ + +
8 Hickey et al17 +
9 Margolese & Chouinard18 +
10 Carcia Lopez et al19 ++ + +
11 Levenson20 ++ + +
12 Gheorghiou et al21 ++
13 Haggarty et al22 ++
14 Nyfort-Hansen & Alderman23 ++ + +
15 Jarventausta & Leinonen24 ++ +
16 Stanfield & Privette25 ++ +
17 Sierra-Biddle et al26 ++ + +
MS, Mental status changes; A, Agitation; MY, Myoclonus; H, Hyperreflexia; D, Diaphoresis; S, Shivering; T, Tremor; DI, Diarrhea; I, Incoordination; 
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cases induced by antipsychotics or selective serotonin-
receptor inhibitors (SSRI's) [7,8].
The atypical or moderate forms of NMS attributed to
novel antipsychotics (that have greater affinity to serot-
onin 5-HT2A receptors than to dopamine D2 receptors)
and the overlapping in clinical features between SS and
NMS observed in patients treated with olanzapine, rein-
force the view that the two syndromes may share the same
underlying pathophysiology, i.e. imbalance between
aminergic systems, despite differences in the causative
drugs [28].
According to Fink [29], NMS and SS are non-specific gen-
eralized neurotoxic syndromes. This author recommends
the immediate withdrawal of the offending agent and the
administration of benzodiazepines in the early stages in
both these syndromes.
Further studies, particularly of prospective nature are war-
ranted in patients receiving conventional or atypical
antipsychotics as well as serotoninergic agents in order to
elucidate the common elements between NMS and SS
regarding phenomenology, pathophysiology and treat-
ment response.
Study limits
This is a retrospective analysis of the reported NMS cases
induced by olanzapine. The fact that the data were col-
lected from published case reports by other authors, has
an inherent bias. The major limitation of this study stems
from the lack of detailed information provided regarding
the SS clinical symptoms, since the authors were mainly
focusing on the description of NMS symptomatology.
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